The reason OREX didn't drop more was that institutions still believe in FDA approval in September and they bought more shares from paniced retail investors. If you listen to today's cc (still on OREX website), you will know there is nothing to worry about. Post-marketing obligation is THE ONLY ISSUE, which takes more time for an agreement to be worked out. The company is confident it will be achieved within the extened time frame.
Good entry point at this level.
Everyone ought to listen to yesterday's CC on OREX website, which explians the reason clearly. NO SAFETY ISSUE, the FDA DOES NOT DISPUTE the light study result. My take is that the company management is trying to negotiate post-marketing obligations to its favor. A smart move to that effect.